San Diego-dependent Viking Therapeutics marked by itself as a serious competitor in the weight loss drug sector in February soon after revealing promising information from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided as being a weekly injection As well as in Marc